ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

Cobimetinib Plus Paclitaxel in TNBC

Adam M. Brufsky, MD, PhD
Published Online:4:55 PM, Wed February 1, 2017

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses combining cobimetinib (Cotellic) and paclitaxel as a first-line treatment in patients with advanced triple-negative breast cancer (TNBC).
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.